ABSTRACT: A "second generation" γ-secretase, Begacestat (GSI-953), which is more selective against Notch-signaling, has shown promise in recent Phase I clinical trials. Begacestat, a novel, 2,5-disubsitituted thiophene sulfonamide from Wyeth (now Pfizer) is under evaluation for the treatment of Alzheimer's disease.
discovered compounds 9 and 10, with much improved potency against Aβ production (Table 1) . 5 Both compounds were >200-fold more potent than the lead compound 1 and showed improved selectivity against Notch, an important protein involved in cell development and differentiation. Unfortunately, these compounds displayed poor stability in human microsomes (t 1/2 < 10 min). The metabolic instability was thought to be mainly due to oxidation of the alkyl groups; thus, contraction of the side chain of 10 led to the discovery of GSI-953 (begacestat, 5). GSI-953 displayed significant improvement in human stability (t 1/2 > 90 min.) while maintaining potency against Aβ production and selectivity versus Notch. 5 Begacestat was further characterized in a number of preclinical assays and has been dosed in healthy human volunteers. 6 As was reported in the lead optimization paper, 5 begascestat was shown to inhibit Aβ production in the low nanomolar range (Aβ 40 EC 50 = 14.8 nM and Aβ 42 EC 50 = 12.4 nM) in both cellular and cell-free assays. The group also reported on a close analogue of GSI-953 (WAY-210952, the (R)-isomer), which was shown to have much reduced potency (>10 μM) for Aβ production inhibition. Evaluation in the APPoverexpressing Tg2576 transgenic mice showed that begacestat, when dosed orally, produced significant reduction of Aβ levels in plasma, brain and CSF levels. 6 When dosed at 100 mg/kg, begacestat produced an ∼88% reduction in CSF and plasma at 2−6 h time points, and produced an ∼60% reduction in brain levels at 6 h. In addition, a 30 mg/kg dose of begacestat displayed a maximal reduction of Aβ 40/42 levels between 4 and 6 h when studied in a 24 h time course study in the brain. Using the same Tg2576 mice, the minimal effective dose (MED) was determined to be 1 mg/kg for Aβ 40 reduction, with significant reduction in both Aβ 40/42 at 2.5 mg/kg. 6 The group also looked at the reversal of contextual memory deficits in Tg2576 mice, a test of hippocampal dependent learning in preplaque animals, and found that begacestat reversed these deficits in a dosedependent manner from 2.5−10 mg/kg, whereas the (R)-isomer showed no effect (30 mg/kg). Lastly, the group reported the initial study in healthy human volunteers. The study looked at single dose administration (3−600 mg) in young subjects (18−55 years old) and found the compound produced dose-dependent changes in plasma Aβ demonstrating target engagement in humans. 6 Based on these exciting preclinical and first-in-human studies, and the lack of Notch-related toxicity in rats and dogs, 6 begacestat has been progressed to more advanced clinical trials.
7 Although the promise of this molecule is high due to the preliminary results, it still remains to be seen if begacestat can be the first γ-secretase inhibitor to be approved for the treatment of AD.
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